A pivotal Phase 2b study of Betalutin in patients with relapsed 3rd line anti-CD 20 Ab-refractory Follicular Lymphoma

Trial Profile

A pivotal Phase 2b study of Betalutin in patients with relapsed 3rd line anti-CD 20 Ab-refractory Follicular Lymphoma

Planning
Phase of Trial: Phase II

Latest Information Update: 28 Nov 2017

At a glance

  • Drugs Lutetium-(177lu) lilotomab satetraxetan (Primary)
  • Indications Follicular lymphoma
  • Focus Registrational; Therapeutic Use
  • Acronyms PARADIGME
  • Sponsors Nordic Nanovector
  • Most Recent Events

    • 28 Nov 2017 New trial record
    • 22 Nov 2017 According to a Nordic Nanovector media release, the company anticipates data read-out and first submission for marketing approval in the second half of 2019.
    • 22 Nov 2017 According to a Nordic Nanovector media release, the company has submitted protocol amendment to regulatory authorities and subjects to approval patient screening anticipated before end of 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top